KEEP Summary Figures S40. Am J Kidney Dis. 2012;59(3)(suppl 2):S40-S64

Similar documents
KEEP Summary Figures S32. Am J Kidney Dis. 2011;57(3)(suppl 2):S32-S56

KEEP 2009 Summary Figures

KEEP S u m m a r y F i g u r e s. American Journal of Kidney Diseases, Vol 53, No 4, Suppl 4, 2009:pp S32 S44.

H e alth his to r y. Chapter 3 Health history. s29

A n aly tical m e t h o d s

Analytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health

S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153

KEEP 2.0 Annual Data Report Chapter Five

Kidney Early Evaluation Program KEEP. A n n u a l D a t a R e p o r t

KEEP 2005 Annual Data Report

Chapter 1: CKD in the General Population

Chronic kidney disease (CKD) has received

EXECUTIVE SUMMARY S3. ONE Program Introduction S5. TWO Participant Characteristics S16. THREE Obesity & Body Mass Index S28

patient characteriuics Chapter Two introduction 58 increasing complexity of the patient population 60 epo use & anemia in the pre-esrd period 62

Supplementary Online Content

As evidenced by a recent analysis of National

Chapter 1: CKD in the General Population

Chapter Two Renal function measures in the adolescent NHANES population

Addressing Chronic Kidney Disease in People with Multiple Chronic Conditions

Supplementary Online Content

Chronic Kidney Disease

Know Your Number Aggregate Report Single Analysis Compared to National Averages

AAll s well that ends well; still the fine s the crown; Whate er the course, the end is the renown. WILLIAM SHAKESPEARE, All s Well That Ends Well

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?

Chapter 2: Identification and Care of Patients With CKD

The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009

Chapter Two Incidence & prevalence

Outline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?

Guest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2

TREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?

KEEP Data Report Chapter 1: Introduction

Chapter 2: Identification and Care of Patients With Chronic Kidney Disease

USRDS UNITED STATES RENAL DATA SYSTEM

Supplementary Appendix

CKDinform: A PCP s Guide to CKD Detection and Delaying Progression

Cirrhosis and Liver Cancer Mortality in the United States : An Observational Study Supplementary Material

Diabetes Mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES)

Outline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011

Prevalence of Self-Reported Obesity Among U.S. Adults by State and Territory. Definitions Obesity: Body Mass Index (BMI) of 30 or higher.

Chapter 2: Identification and Care of Patients With CKD

CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH

Disclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW

CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW

Outline. Introduction. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 6/26/2012

Disclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW

A New Approach for Evaluating Renal Function and Predicting Risk. William McClellan, MD, MPH Emory University Atlanta

Obesity Trends:

Chronic Kidney Disease: Optimal and Coordinated Management

Creatinine & egfr A Clinical Perspective. Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC

2013 Hypertension Measure Group Patient Visit Form

2011 Dialysis Facility Report

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

2012 Medicaid and Partnership Chart

CHRONIC DISEASE PREVALENCE AMONG ADULTS IN OHIO

2011 Dialysis Facility Report SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE Dialysis Facility Report SAMPLE

Cancer Prevention & Early Detection Facts & Figures. Tables and Figures 2018

Ashberyh CHAPTER. John

Update on HIV-Related Kidney Diseases. Agenda

Diabetic Kidney Disease in the Primary Care Clinic

Cessation and Cessation Measures

CKD and risk management : NICE guideline

Screening and early recognition of CKD. John Ngigi (FISN) Kidney specialist

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

Chapter 2: Identification and Care of Patients with CKD

Kidney Disease, Hypertension and Cardiovascular Risk

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

ACEP National H1N1 Preparedness Survey Results

Status of the CKD and ESRD treatment: Growth, Care, Disparities

Diabetes and Hypertension

Statistical Fact Sheet Populations

Clinical Approach to the Patient At-Risk for Kidney Disease: Rationale for Testing for Serum Creatinine and Albuminuria

Classification of CKD by Diagnosis

Standards of Medical Care in Diabetes 2016

Exhibit 1. Change in State Health System Performance by Indicator

Section 1: 1: Trends. Section 2: 2: Comparisons to to Overall Portland Area Area Results for for

National Deaf Center on Postsecondary Outcomes. Data Interpretation Guide for State Reports: FAQ

year resident, Department of Medicine, B. J. Medical college, Ahmedabad.

FULFILLMENT OF K/DOQI GUIDELINES 92 anemia treatment dialysis therapy vascular access

Women s health status is one of the strongest determinants of how women use the health care system. The

T. Suithichaiyakul Cardiomed Chula

Cardiovascular Risk Reduction in Kidney Transplant Recipients

Management of Early Kidney Disease: What to do Before Referring to the Nephrologist

Summary of Recommendation Statements Kidney International Supplements (2013) 3, 5 14; doi: /kisup

DIABETES. A growing problem

QUICK REFERENCE FOR HEALTHCARE PROVIDERS

SUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Geographical Accuracy of Cell Phone Samples and the Effect on Telephone Survey Bias, Variance, and Cost

Evaluation of Chronic Kidney Disease KDIGO. Paul E de Jong University Medical Center Groningen The Netherlands

INDEX WORDS: Awareness; chronic kidney disease; Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI); estimated glomerular filtration rate.

The 2004 National Child Count of Children and Youth who are Deaf-Blind

egfr > 50 (n = 13,916)

The Metabolic Syndrome: Is It A Valid Concept? YES

Radiation Therapy Staffing and Workplace Survey 2016

ARE STATES DELIVERING?

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015

Which Hospitals Treat Patients with the Most Severe Acute Ischemic Strokes? Implications for Hospital Mortality Reporting

The Wellbeing of America s Workforce, and Its Effects on an Organization s Performance

NCDB The National Center on Deaf-Blindness

Transcription:

211 Summary Figures S4 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64

Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving medication for diabetes, or elevated blood glucose (WHO); fasting blood sugar 126 mg/dl or nonfasting blood sugar 2 mg/dl, or A1c 7% (if available) SELF-REPORTED DIABETES Self-reported diabetes or self-reported diabetic retinopathy GLYCEMIC CONTROL Fasting blood sugar <126 mg/dl or non-fasting blood sugar <2 mg/dl, and A1c <7% (if available) HYPERTENSION Self reported history hypertension, receiving a medication for hypertension, or elevated blood pressure (JNC7): Diabetes or ; systolic 13 mmhg or diastolic 8 mmhg, otherwise systolic 14 mmhg or diastolic 9 mmhg SELF-REPORTED HYPERTENSION Self-reported hypertension BLOOD PRESSURE CONTROL Diabetes or : systolic <13 mmhg and diastolic <8 mmhg, otherwise systolic <14 mmhg and diastolic <9 mmhg HIGH CHOLESTEROL Self-reported high cholesterol or receiving medication for cholesterol, or cholesterol level >2 mg/dl SELF-REPORTED HIGH CHOLESTEROL Self-reported high cholesterol CHOLESTEROL CONTROL Total cholesterol levels of 2 mg/dl SELF-REPORTED CARDIOVASCULAR DISEASE Participant reports any of the following cardiac events: heart attack, bypass surgery, heart angioplasty, stroke, heart failure, abnormal heart rhythm, or PVD (only for version 2) MICROALBUMINURIA Albumin/creatinine ratio 3 mg/g CHRONIC KIDNEY DISEASE egfr <6 ml/min/1.73 m 2 or egfr 6 ml/min/1.73 m 2 and albumin-creatinine ratio (ACR) 3 mg/g. GFR estimated using the IDMS-traceable 4-variable Modification of Diet in Renal Disease (MDRD) Study equation or Chronic Kidney Disease Epidemiology Collaboration equation (-EPI) for calibrated serum creatinine (Scr) values STAGES Stage 1: egfr 9 ml/min/1.73 m 2, and ACR 3 mg/g Stage 2: egfr 6 89 ml/min/1.73 m 2, and ACR 3 mg/g Stage 3: egfr 3 59 ml/min/1.73 m 2 Stage 4: egfr 15 29 ml/min/1.73 m 2 Stage 5: egfr <15 ml/min/1.73 m 2 ANEMIA WHO Male: hemoglobin <13 g/dl Female: <12g/dl KDOQI (26) Males: hemoglobin <13.5 g/dl Women <12g/dl BODY MASS INDEX CATEGORIES UW: underweight, BMI <18.5 N: normal, BMI 18.5 24.9 OW: overweight, BMI 25 29.9 OB: obese, BMI 3 39.9 EOB: extremely obese, BMI 4 EDUCATIONAL STATUS GSL: Grade school or less SHS: Some high school HSG: High school graduate SC+: Some college, college graduate, post-graduate NHANES 1999 26 DATA ANALYSES SELF-REPORTED DIABETES To be classified as having self-reported diabetes, participants had to report being told by a doctor, at any time, that they had diabetes or sugar diabetes other than that related to pregnancy. Participants answering borderline to the question were classified as non-diabetic. SELF-REPORTED HYPERTENSION Self-reported hypertension was identified by an affirmative answer to the question: Have you ever been told by a doctor that you had hypertension, also called high blood pressure. SELF-REPORTED HIGH CHOLESTEROL Self-reported high cholesterol was identified by an affirmative answere to the question: Have you ever been told by a doctor or other health professional that your blood cholesterol level was high? SELF-REPORTED CARDIOVASCULAR DISEASE Participant reports any of the following cardiac events: coronary heart disease, angina/angina pectoris, heart attack, congestive heart failure, or stroke. MICROALBUMINURIA Albumin/creatinine ratio 3 mg/g CHRONIC KIDNEY DISEASE egfr <6 ml/min/1.73 m 2 or egfr 6 ml/min/1.73 m 2 and albumin-creatinine ratio (ACR) 3 mg/g. GFR estimated using the IDMS-traceable 4-variable Modification of Diet in Renal Disease (MDRD) Study equation or Chronic Kidney Disease Epidemiology Collaboration equation (-EPI) for calibrated serum creatinine (Scr) values STAGES Stage 1: egfr 9 ml/min/1.73 m 2, and ACR 3 mg/g Stage 2: egfr 6 89 ml/min/1.73 m 2, and ACR 3 mg/g Stage 3: egfr 3 59 ml/min/1.73 m 2 Stage 4: egfr 15 29 ml/min/1.73 m 2 Stage 5: egfr <15 ml/min/1.73 m 2 ANEMIA WHO Male: hemoglobin <13 g/dl Female: <12g/dl KDOQI (26) Males: hemoglobin <13.5 g/dl Women <12g/dl BODY MASS INDEX CATEGORIES UW: underweight, BMI <18.5 N: normal, BMI 18.5 24.9 OW: overweight, BMI 25 29.9 OB: obese, BMI 3 39.9 EOB: extremely obese, BMI 4 EDUCATIONAL STATUS GSL: Grade school or less HSG: High school graduate SC+: Some college, college graduate, post graduate Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64 S41

Program accessibility cumulative # of partic. (in 1,s) 15 125 1 75 5 25 5 138,65 48 Cumulative # of affiliates 25-1 2 3 4 5 6 7 8 9 1-1 2 3 4 5 6 7 8 9 1 45 4 35 3 s.1 Cumulative number of eligible participants & affiliates, by year (2 21), N = 138,65 s.2 Geographic variations in the percent of participants, by state (2 21), N = 138,65 Percent of participants 3.42 + ( 4.89) 1.85 to <3.42.92 to <1.85.38 to <.92 Below.38 (.13) South Carolina Florida Indiana Utah Greater New York Western Pennsylvania Mass./Rhode Isl./N. Hampshire/Vermont Virginia Louisiana East Tennessee Connecticut Kentucky North Carolina National Capital Area Georgia Arizona Minnesota North Texas Hawaii Ohio 1 2 3 4 5 6 Percent of participants s.3 Twenty largest affiliates, by percentage of participants screened (rank order) (2 21), N = 95,813 S42 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64

Program accessibility s.a Total eligible participants, by year (2 21), N = 138,65 Age 2+21 22 23 24 25 26 27 28 29 21 All All (%) 18-3 568 644 1,4 1,85 1,391 1,257 989 1,77 1,19 71 9,735 7. 31-45 1,491 1,977 2,393 2,939 3,984 3,685 2,87 3,4 2,697 2,135 27,175 19.6 46-6 2,97 2,651 3,422 4,69 6,438 6,592 5,59 6,113 5,949 4,824 48,285 34.8 61-75 1,52 2,29 2,382 3,328 4,769 5,111 4,968 5,562 5,575 4,663 39,889 28.8 >75 424 743 721 1,76 1,547 1,656 1,683 1,938 1,959 1,774 13,521 9.8 Missing............ Gender Male 1,959 2,57 2,944 4,142 5,879 5,684 5,27 5,85 5,547 4,464 44,21 31.9 Female 4,123 5,473 6,976 8,975 12,192 12,613 1,88 11,889 11,65 9,629 94,328 68.1 Missing. 1 2 1 58 4 4. 2 4 76.1 Race White 2,284 3,14 4,31 5,793 9,28 9,8 8,131 9,261 8,738 7,251 66,899 48.3 Black 2,652 3,392 3,43 4,274 5,267 5,565 5,41 5,42 5,479 4,476 44,978 32.5 Native American 324 575 686 818 723 434 346 153 275 132 4,466 3.2 Asian 172 263 423 477 952 1,228 851 1,76 875 85 7,167 5.2 Pacific Islander 55 133 113 45 92 24 12 114 52 75 715.5 Other 416 387 629 1,629 1,647 1,256 1,123 1,37 1,78 1,255 11,357 8.2 Unknown/missing 179 19 34 82 42 786 515 381 72 58 3,23 2.2 Ethnicity Hispanic 618 712 1,117 1,89 2,416 2,317 2,75 2,163 2,317 1,851 17,476 12.6 Non-Hispanic 5,464 7,332 8,85 11,228 15,713 15,984 13,944 15,531 14,882 12,246 121,129 87.4 Education Level <12 years 948 1,277 1,42 2,2 2,83 2,782 2,469 2,454 2,353 1,758 2,293 14.6 12 years 1,585 2,192 2,591 3,491 4,611 4,462 4,19 4,531 4,527 3,73 35,91 25.9 >12 years 1,629 2,155 2,775 3,459 4,675 4,351 3,815 4,54 4,272 3,56 35,141 25.4 16 years 1,143 1,463 1,913 2,53 3,614 3,814 3,228 3,682 3,738 3,274 28,399 2.5 >16 years 688 862 1,132 1,467 2,145 2,453 2,19 2,299 2,117 1,769 16,951 12.2 Missing 89 95 91 169 254 439 297 224 192 6 1,91 1.4 Health Insurance Status Yes 4,948 6,428 7,892 1,153 14,56 14,27 12,44 13,631 12,579 1,577 16,875 77.1 No 883 1,234 1,66 2,49 3,251 3,371 3,292 3,525 3,88 3,196 26,782 19.3 Missing 251 382 37 475 822 723 318 536 74 323 4,94 3.6 All 6,82 8,44 9,922 13,118 18,129 18,31 16,19 17,694 17,199 14,97 138,65 1 "." Zero values in this cell Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64 S43

Targeting high-risk populations % with self-reported diabetes 4 3 2 1 29.9 6.9 NHANES 99-6 All 18-3 31-45 46-6 61-75 75+ s.4 Self-reported diabetes in & NHANES participants (2 21), N= 137,765 NHANES (1999 26), N= 22,66 5 s.5 participants with diabetes Percent with diabetes 4 3 2 1 31.3 (2 21), N= 138,58 All 18-3 31-45 46-6 61-75 75+ White Black Oth Hisp NHisp Percent aware 1 8 6 4 2 95. s.6 participants with diabetes who are aware of their condition (2 21), N= 43,314 All 18-3 31-45 46-6 61-75 75+ Percent treated 6 5 4 3 2 1 47.3 s.7 participants with diabetes who receive medication for their condition (2 21), N= 43,314 All 18-3 31-45 46-6 61-75 75+ S44 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64

Targeting high-risk populations Percent with glycemic control 1 8 6 4 2 All 18-3 31-45 46-6 61-75 75+ s.8 Glycemic control in participants with diabetes (2 21), N= 43,314 Percent with glycemic control 1 8 6 4 2 59.9 All 18-3 31-45 46-6 61-75 75+ s.9 Glycemic control in participants with diabetes who are being treated for their condition (2 21), N= 2,487 Percent with glycemic control 1 8 6 4 2 7.9 All 18-3 31-45 46-6 61-75 75+ s.1 Glycemic control in participants with diabetes who are not being treated for their condition (2 21), N= 22,827 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64 S45

Targeting high-risk populations s.11 % with self-reported hypertension 8 6 4 2 56.4 26.9 NHANES 99-6 All 18-3 31-45 46-6 61-75 75+ Self-reported hypertension in & NHANES participants (2 21), N= 136,922 NHANES (1999 26), N= 22,366 s.12 1 participants with hypertension Percent with hypertension 8 6 4 2 7.4 (2 21), N= 138,588 All 18-3 31-45 46-6 61-75 75+ Percent aware 1 8 6 4 2 s.13 participants with hypertension who are aware of their condition (2 21), N= 97,567 All 18-3 31-45 46-6 61-75 75+ Percent treated 1 8 6 4 2 62.1 s.14 participants with hypertension who receive medication for their condition (2 21), N= 97,567 All 18-3 31-45 46-6 61-75 75+ S46 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64

Targeting high-risk populations s.15 4 Blood pressure control in participants with hypertension Percent controlled 3 2 1 26.8 (2 21), N= 97,567 All 18-3 31-45 46-6 61-75 75+ Percent controlled 5 4 3 2 1 32.2 s.16 Blood pressure control in participants with hypertension who are being treated for their condition (2 21), N= 6,553 All 18-3 31-45 46-6 61-75 75+ Percent controlled 4 3 2 1 18. s.17 Blood pressure control in participants with hypertension not being treated for their condition (2 21), N= 37,14 All 18-3 31-45 46-6 61-75 75+ Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64 S47

Targeting high-risk populations % with self-reported high chol. 1 8 6 4 2 5.7 38.7 NHANES 99-6 NHANES: age 2-3 All 18-3 31-45 46-6 61-75 75+ s.18 Self-reported high cholesterol in & NHANES participants (2 21), N= 69,463 NHANES (1999 26), N= 13,535 Percent with high cholesterol 1 8 6 4 2 62.2 All 18-3 31-45 46-6 61-75 75+ s.19 participants with high cholesterol (2 21), N= 94,28 Percent aware 1 8 6 4 2 6.1 s.2 participants with high cholesterol who are aware of their condition (2 21), N= 58,623 All 18-3 31-45 46-6 61-75 75+ Percent treated 6 4 2 32.6 s.21 participants with high cholesterol who receive medication for their condition (2 21), N= 58,623 All 18-3 31-45 46-6 61-75 75+ S48 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64

Targeting high-risk populations Percent controlled 5 4 3 2 1 31.6 s.22 Cholesterol control in participants with high cholesterol (2 21), N= 58,623 All 18-3 31-45 46-6 61-75 75+ Percent controlled 1 8 6 4 2 7.2 s.23 Cholesterol control in participants with high cholesterol who are being treated for their condition (2 21), N= 19,118 All 18-3 31-45 46-6 61-75 75+ Percent controlled 2 15 1 5 12.9 s.24 Cholesterol control in participants with high cholesterol who are not being treated for their condition (2 21), N= 39,55 All 18-3 31-45 46-6 61-75 75+ Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64 S49

Targeting high-risk populations s.25 % with self-reported CVD 5 4 3 2 1 Age 23. Gender Race/ethnicity Self-reported cardiovascular disease in participants (2 21), N= 135,582 All 18-3 31-45 46-6 61-75 75+ White Black Other Hisp OW: 33.1 NHANES 99-6 N: 21.4 UW:.9 OW: 33.6 EO: 8.9 N: 32.8 UW: 1.9 EOB: 5.1 s.26 Percent distribution of & NHANES participants, by BMI (2 21), N= 137,5 NHANES (1999 26), N= 2,567 OB: 35.67 OB: 26.5 S5 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64

Prevalence of 75 Age: MDRD Gender Race/ethnicity s.27 Prevalence of in & NHANES participants Percent with 5 25.9 25 15.3 -EPI 75 NHANES 99-6 (2 21), N= 124,41 NHANES (1999 26), N= 19,553 5 25 23.7 14.1 NHANES 99-6 All 18-3 31-45 46-6 61-75 75+ White Black Other Hisp Percent with microalbuminuria 3 2 1 11.7 9.6 NHANES 99-6 All 18-3 31-45 46-6 61-75 75+ White Black Other Hisp s.28 Prevalence of microalbuminuria in & NHANES participants (2 21), N= 127,593 NHANES (1999 26), N= 2,573. Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64 S51

Prevalence of s.b Total eligible participants with, by stage: MDRD equation (2 21), N= 138,65 Stage 1 & Stage 2 & Non- Abnormal ACR Abnormal ACR Stage 3 Stages 4-5 Missing All Age 18-3 7,489 462 198 139 17 1,43 9,735 31-45 2,465 97 942 1,129 68 3,61 27,175 46-6 34,634 1,43 2,46 4,927 243 5,32 48,285 61-75 23,799 617 2,174 9,551 468 3,28 39,889 >75 5,584 115 848 5,635 438 91 13,521 Gender Male 29,64 1,52 2,158 6,3 459 4,628 44,21 Female 62,367 2,515 4,5 15,81 775 9,54 94,328 Missing..... 76 76 Race White 43,417 1,65 2,911 14,79 714 4,713 66,899 Black 3,731 1,629 2,121 4,624 34 5,569 44,978 Native American 2,791 226 247 598 59 545 4,466 Asian 5,32 194 32 776 63 494 7,167 Pacific Islander 421 23 63 117 13 78 715 Other 8,392 385 493 1,96 78 913 11,357 Unknown/missing 899 45 53 91 3 1,932 3,23 Ethnicity Hispanic 12,121 595 66 1,446 94 2,56 17,476 Non-Hispanic 79,85 2,972 5,548 19,935 1,14 11,684 121,129 U.S. Census Region Northeast 22,7 834 1,526 5,154 281 3,63 32,928 Midwest 13,617 537 923 3,442 192 1,989 2,7 South 42,78 1,725 2,84 9,198 525 7,435 64,53 West 13,483 471 919 3,581 236 1,746 2,436 Missing 21.. 6. 11 38 U.S. Census Division New England 7,113 241 483 1,95 89 1,666 11,497 Middle Atlantic 14,957 593 1,43 3,249 192 1,397 21,431 East North Central 8,619 374 595 1,953 11 1,3 12,654 West North Central 4,998 163 328 1,489 82 986 8,46 South Atlantic 22,14 877 1,444 4,824 258 4,279 33,696 East South Central 11,37 46 766 2,578 128 1,369 16,617 West South Central 9,396 442 63 1,796 139 1,787 14,19 Mountain 7,683 248 492 2,431 128 924 11,96 Pacific 5,8 223 427 1,15 18 822 8,53 Missing 21.. 6. 11 38 Smoking Yes 34,397 1,483 2,657 8,724 548 5,571 53,38 No 54,736 1,952 3,365 11,984 647 7,812 8,496 Missing 2,838 132 186 673 39 861 4,729 Education Level < 12 years 12,256 654 1,71 3,595 269 2,448 2,293 12 years 22,935 97 1,78 6,328 385 3,584 35,91 >12 years 23,65 927 1,516 5,91 293 3,664 35,141 16 years 2,23 677 1,146 3,537 162 2,647 28,399 >16 years 11,87 294 664 2,55 11 1,526 16,951 Missing 1,92 45 13 28 15 375 1,91 Health Insurance Status Yes 69,623 2,366 4,791 18,275 1,31 1,789 16,875 No 19,388 1,59 1,21 2,224 148 2,762 26,782 Missing 2,952 142 216 882 55 693 4,94 Doctor Status Yes 79,143 2,967 5,563 2,72 1,15 11,841 12,736 No 11,175 523 535 948 56 1,928 15,165 Missing 1,653 77 11 361 28 475 2,74 All 91,971 3,567 6,28 21,381 1,234 14,244 138,65 "." Zero values in this cell S52 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64

Prevalence of 3 2 MDRD 25.9 15.3 NHANES 99-6 s.29 Prevalence of in & NHANES participants, by stage (2 21), N= 124,41 NHANES (1999 26), N= 19,553 1 Percent with 3 2 -EPI 23.7 NHANES 99-6 14.1 1 All Stage 1 Stage 2 Stage 3 Stages 4-5 s.3 1 8 6 MDRD NHANES 99-6 Prevalence of in & NHANES participants, by risk factor (2 21), N= 123,463 NHANES (1999 26), N= 19,354 Percent with 4 2 1 25.8 -EPI 15.3 8 6 4 2 23.6 14.1 NHANES 99-6 All No /DM /HTN /DM/HTN /Other Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64 S53

Prevalence of s.c Total eligible participants with, by stage: -EPI equation (2 21), N= 138,65 Stage 1 & Stage 2 & Non- Abnormal ACR Abnormal ACR Stage 3 Stages 4-5 Missing All Age 18-3 7,542 578 92 69 15 1,439 9,735 31-45 2,958 1,414 575 486 66 3,676 27,175 46-6 36,85 1,843 1,87 3,173 213 5,164 48,285 61-75 24,873 74 2,17 8,262 476 3,368 39,889 >75 5,239 43 854 5,984 543 858 13,521 Gender Male 3,83 1,35 1,968 5,668 58 4,669 44,21 Female 64,614 3,313 3,53 12,36 85 9,76 94,328 Missing..... 76 76 Race White 45,515 1,515 2,664 11,544 754 4,97 66,899 Black 3,859 1,947 1,827 4,426 349 5,57 44,978 Native American 2,884 284 221 459 6 558 4,466 Asian 5,437 256 29 612 62 51 7,167 Pcific Islander 446 42 5 79 12 86 715 Other 8,635 522 394 791 73 942 11,357 Unknown/missing 921 52 52 63 3 1,932 3,23 Ethnicity Hispanic 12,433 767 547 1,39 9 2,6 17,476 Non-Hispanic 82,264 3,851 4,951 16,935 1,223 11,95 121,129 U.S. Census Region Northeast 22,719 1,67 1,375 4,338 298 3,131 32,928 Midwest 14,56 692 826 2,919 27 2, 2,7 South 43,9 2,26 2,487 7,768 569 7,573 64,53 West 14,1 653 81 2,943 239 1,79 2,436 Missing 21.. 6. 11 38 U.S. Census Division New England 7,414 314 442 1,525 93 1,79 11,497 Middle Atlantic 15,35 753 933 2,813 25 1,422 21,431 East North Central 8,848 47 539 1,668 119 1,1 12,654 West North Central 5,28 222 287 1,251 88 99 8,46 South Atlantic 22,574 1,13 1,261 4,9 276 4,365 33,696 East South Central 11,72 53 674 2,178 148 1,385 16,617 West South Central 9,624 546 552 1,5 145 1,823 14,19 Mountain 8,47 337 446 2,9 133 934 11,96 Pacific 5,954 316 364 934 16 856 8,53 Missing 21.. 6. 11 38 Smoking Yes 35,415 1,96 2,365 7,425 589 5,68 53,38 No 56,369 2,556 2,96 9,968 683 7,96 8,496 Missing 2,913 156 173 581 41 865 4,729 Education Level <12 years 12,481 774 991 3,26 31 2,477 2,293 12 years 23,649 1,211 1,565 5,416 416 3,653 35,91 >12 years 24,379 1,228 1,319 4,26 293 3,716 35,141 16 years 2,883 942 948 2,746 163 2,717 28,399 >16 years 12,187 41 584 2,12 114 1,563 16,951 Missing 1,117 62 91 244 17 379 1,91 Health Insurance Status Yes 71,769 3,57 4,327 15,612 1,114 1,996 16,875 No 19,899 1,396 97 1,571 14 2,86 26,782 Missing 3,21 165 21 791 59 73 4,94 Doctor Status Yes 81,569 3,849 4,966 17,46 1,233 12,73 12,736 No 11,428 683 418 633 53 1,95 15,165 Missing 1,7 86 114 295 27 482 2,74 All 94,697 4,618 5,498 17,974 1,313 14,55 138,65 "." Zero values in this cell S54 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64

as a disease multiplier s.31 5 4 MDRD:, Age 41.4 No Gender Race/ethnicity Self-reported diabetes in & NHANES participants with or without 3 2 26.5 (2 21), N= 122,453 NHANES (1999 26), N= 19,542 1 5 NHANES 99-6 Percent with self-reported diabetes 4 3 2 1 5 4 3 2 1 19.7 4.6 * -EPI: 42.7 26.5 No NHANES 99-6 5 4 3 2 1 2.6 4.6 * All 18-3 31-45 46-6 61-75 75+ White Black Other Hisp Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64 S55

as a disease multiplier 1 8 6 4 2 1 8 6 MDRD:, 73.9 NHANES 99-6 52. 51.3 No s.32 Self-reported hypertension in & NHANES participants with or without (2 21), N= 121,762 NHANES (1999 26),N= 19,36 Percent with self-reported hypertension 4 2 1 8 6 4 2 1 8 6 4 2 -EPI: 75.6 22.6 NHANES 99-6 53.1 51.5 22.9 No All 18-3 31-45 46-6 61-75 75+ White Black Other Hisp S56 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64

as a disease multiplier 1 8 6 4 2 1 MDRD:, 62. 47.2 NHANES 99-6 No s.33 Self-reported high cholesterol in & NHANES participants with or without (2 21), N= 66,279 NHANES (2 29), N= 11,781 Percent with self-reported high cholesterol 8 6 4 2 1 8 6 4 2 1 8 48.3 -EPI: 62.2 37.2 47.5 NHANES 99-6 NHANES: age 2-3 No NHANES: age 2-3 6 4 2 49 37 All 18-3 31-45 46-6 61-75 75+ White Black Other Hisp Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64 S57

as a disease multiplier 5 4 3 MDRD: Age 34.2 No Gender Race/ethnicity s.34 Self-reported cardiovascular disease in KEEp participants with or without (2 21), N= 124,41 2 2.3 % with self-reported CVD 1 5 4 3 -EPI 33.1 No 2 2.3 1 All 18-3 31-45 46-6 61-75 75+ White Black Other Hisp 8 6 4 MDRD:, Age 46.4 44. No Gender s.35 BMI 3 kg/m 2 in & NHANES participants with or without (2 21), N= 122,756 NHANES (1999 26), N=19,148 2 8 NHANES 99-6 6 Percent with BMI>= 3kg/m 2 4 2 8 6 4 37.7 3.6 -EPI: 46.2 44.1 No 2 8 NHANES 99-6 6 4 38.2 3.6 2 All 18-45 46-6 61+ Male Female S58 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64

as a disease multiplier % of participants with anemia 3 2 1 3 2 MDRD: WHO anemia 12.2 -EPI 5.4 NHANES 99-6 NHANES 99-6 KDOQI anemia 14.3 6.4 s.36 Anemia (WHO & KDOQI definitions) in & NHANES participants with or without (2 21), N= 122,461 NHANES (1999 26), N= 19,533 1 12.2 5.4 14.3 6.4 All No All No 8 6 4 2 8 MDRD: WHO anemia NHANES 99-6 Male Female 9.4 13.4 3. 7.7 KDOQI anemia * s.37 Anemia (WHO & KDOQI definitions) in & NHANES participants (2 21), N= 122,461 NHANES (1999 26), MDRD, N= 19,533, -EPI, N=19,536 6 4 Percent of participants with anemia 2 8 6 4 2 8 16. 13.4 5.1 7.7 -EPI : WHO anemia KODQI anemia Male Female 9.4 13.4 3. 7.7 * * 6 4 2 16. 13.4 5.1 7.7 * All No Stg 1 Stg 2 Stg 3 Stgs 4-5 All No Stg 1 Stg 2 Stg 3 Stgs 4-5 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64 S59

as a disease multiplier s.d Odds ratio (OR) of, by risk factor (2 21), N= 62,715 MDRD equation OR Low Upper P-value Age 18-45.74.69.79 <.1 46-6 1. 61-75 1.84 1.75 1.93 <.1 75+ 4.33 4.6 4.62 <.1 Male.93.9.97. Race White 1. Black.64.61.67 <.1 Native American 1.7.92 1.24.37 Asian.66.59.72 <.1 Other 1.17 1.6 1.29. Hispanic.65.59.71 <.1 Self-reported diabetes 1.42 1.36 1.48 <.1 Self-reported hypertension 1.76 1.68 1.84 <.1 Self-reported high cholestrol 1.11 1.6 1.15 <.1 Cardiovascular disease 1.25 1.19 1.3 <.1 2 1.14 1.1 1.19 <.1 Anemia (WHO definition) 2.9 1.98 2.21 <.1 Insurance.95.9 1..5 -EPI equation OR Low Upper P-value Age 18-45.83.78.89 <.1 46-6 1. 61-75 2.7 1.96 2.18 <.1 75+ 6.29 5.88 6.72 <.1 Male 1.4.99 1.8.13 Race White 1. Black.79.75.83 <.1 Native American 1.19 1.2 1.38.3 Asian.71.64.79 <.1 Other 1.18 1.7 1.31. Hispanic.7.64.77 <.1 Self-reported diabetes 1.48 1.42 1.55 <.1 Self-reported hypertension 1.79 1.71 1.88 <.1 Self-reported high cholestrol 1.9 1.5 1.14 <.1 Cardiovascular disease 1.27 1.22 1.33 <.1 2 1.15 1.1 1.2 <.1 Anemia (WHO definition) 2.22 2.1 2.35 <.1 Insurance.93.88.98.1 S6 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64

Education & insurance SC: 25.7 HSG: 26.3 CG: 2.8 GSL/SHS 14.8 PG: 12.4 NHANES 99-6 HSG: 26.1 GSL: 2.7 SC+: 53.2 s.38 Percent distribution of & NHANES participants, by educational status (2 21), N= 136,694 NHANES (1999 26), N= 22,553 Percent with insurance 1 Age 77.1 81.9 NHANES 99-6 8 6 4 2 Gender s.39 Insurance coverage in & NHANES participants (2 21), N= 138,597 NHANES (1999 26), N= 22,3 All 18-3 31-45 46-6 61-75 75+ Non- Medicare: 38.1 Mcare with other than Mcaid: 12.2 Medicare 11.6 Unknown or missing: 34.8 Mcare/Mcaid: 3.2 s.4 Percent distribution of types of insurance in participants reporting they have insurance (2 21), N= 138,65 Percent with insurance 1 8 6 4 2 NHANES White Black Other Hispanic s.41 Insurance coverage in & NHANES participants (2 21), N= 1 35,574 race, N= 138,597 ethnicity NHANES (1999 26), N= 22,3 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64 S61

RRT & mortality outcomes s.e Hazard ratio of RRT, controlled by risk factors (2 21), N= 11,423 s.f Hazard ratio of death, controlled by risk factors (2 21), N= 11,417 Estimate SE P-value Hazard ratio Age 18-45.31.14.33 1.36 46-6 1. 61-75 -.6.11 <.1.55 75+ -1.8.15 <.1.34 Male.64.9 <.1 1.89 Race White 1. Black.47.11 <.1 1.6 Native American.53.18.39 1.7 Asian.3.2.145 1.35 Other.7.21.7366 1.7 Hispanic -.27.21.1943.76 Self-reported diabetes.48.1 <.1 1.62 Self-reported hypertension.48.16.19 1.62 Cardiovascular disease.14.9.159 1.15 BMI 3 kg/m 2.2.1.8254 1.2 Anemia (WHO definition).92.1 <.1 2.5 Insurance -.7.13.5629.93 egfr(continuous) -.9. <.1.92 ACR 3mg/g 2.26.13 <.1 9.6 MDRD Study Equation Estimate SE P-value Hazard ratio Age 18-45 -.96.9 <.1.38 46-6 1. 61-75.9.5 <.1 2.45 75+ 1.83.6 <.1 6.25 Male.56.3 <.1 1.75 Race White 1. Black -.7.4.8.93 Native American.37.7 <.1 1.44 Asian -.37.9 <.1.69 Other -.31.11.1.74 Hispanic -.24.9.1.79 Self-reported diabetes.34.4 <.1 1.41 Self-reported hypertension.16.4. 1.17 Cardiovascular disease.51.4 <.1 1.66 BMI 3 kg/m 2 -.6.4.9.94 Anemia (WHO definition).57.4 <.1 1.77 Insurance -.18.6..84 by MDRD non- 1. stage 1.76.1 <.1 2.14 stage 2.67.6 <.1 1.95 stage 3-5.59.4 <.1 1.81 -EPI Equation Estimate SE P-value Hazard ratio Age 18-45 -.96.9 <.1.38 46-6 1. 61-75.88.5 <.1 2.41 75+ 1.77.6 <.1 5.87 Male.55.3 <.1 1.73 Race White 1. Black -.1.4.2.91 Native American.36.7 <.1 1.44 Asian -.38.9 <.1.69 Other -.31.11.1.73 Hispanic -.24.9.1.79 Self-reported diabetes.34.4 <.1 1.41 Self-reported hypertension.15.4. 1.17 Cardiovascular disease.51.4 <.1 1.66 BMI 3 kg/m 2.94 Anemia (WHO definition).6. <.1 1.74 Insurance -.18.6..83 by -EPI non- 1. stage 1.75.9 <.1 2.13 stage 2.7.6 <.1 2.1 stage 3-5.64.4 <.1 1.9 S62 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64

RRT & mortality outcomes Rate per 1, person years 3. 2.5 2. 1.5 1..5. 1.4 All 18-3 31-45 46-6 61-75 75+ White Black Other Hisp s.42 Rates of renal replacement therapy (RRT) in participants (2 21), N= 119,718 Rate per 1, person years 1 8 6 4 2 MDRD equation Stage 1 Stage 2 Stages 3-5 -EPI equation Stage 1 Stage 2 Stages 3-5 Rate per 1, person years 4 3 2 1 8.1 All 18-3 31-45 46-6 61-75 75+ White Black Other Hisp s.43 Mortality rates in participants (2 21), N= 122,641 Rate per 1, patient years 3 2 1 MDRD equation Stage 1 Stage 2 Stages 3-5 -EPI equation Stage 1 Stage 2 Stages 3-5 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64 S63

Access, follow-up & intervention Percent with a physician 1 8 6 4 2 Age 88.2 Gender Race/ethnicity s.44 participants with a physician (2 21), N= 135,91 All 18-3 31-45 46-6 61-75 75+ WhiteBlackOther Hisp NHisp % completing followup form 5 4 3 2 1 2+21 22 23 24 25 26 27 28 29 21 s.45 follow-up response rate (%) (2 21), N=138,68 Reasons for seeing a physician (%) 6 4 2 BP Glucose Urine egfr Hgb Cholesterol Other s.46 Reasons for seeing a physician in participants who return their follow-up forms (2 21), N= 35,275 S64 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64